Apellis Pharmaceuticals, Inc. Common Stock (APLS)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 733
- Market Cap
- $5.3B
About Apellis Pharmaceuticals, Inc. Common Stock
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
SentiSense also tracks daily options readings for Apellis Pharmaceuticals, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Apellis Pharmaceuticals, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.